Management guidance suggests operating earnings could nearly double in the following year, signalling a potential inflection point for the healthcare company.
Key Highlights
- Revenue reached $85.1 million, up 4.9% year-on-year
- Net profit improved significantly to -$2.4 million from prior-year losses, representing an 81.1% improvement
- EBIT of $6.0 million indicates underlying operational performance
- Management forecasts operating earnings of $9.0–$12.0 million for FY2020
- Governance rating of 77.24/100 (Very Good) reflects solid corporate standards
Financial Performance
AFT Pharmaceuticals Limited reported full-year revenue of $85.1 million for the 12 months to 31 March 2019, representing a 4.9% increase on the prior corresponding period. Based on available data, this suggests modest but consistent top-line growth during the reporting year.
The company's profitability position appears to have improved materially. Net profit for FY2019 reached -$2.4 million, compared to a larger loss in the prior year, indicating an 81.1% improvement in the bottom line. EBIT of $6.0 million suggests the underlying operational performance was positive, though net profit remained negative due to factors including financing costs or one-off items not detailed in the available data.
Earnings Analysis
The 81.1% improvement in net profit year-on-year indicates AFT moved closer to sustained profitability during FY2019, though the company had not yet achieved a positive net profit position by period end. The gap between EBIT ($6.0 million) and net profit (-$2.4 million) suggests material non-operating expenses or tax impacts that warrant consideration by stakeholders reviewing the full financial statements.
Dividend Update
AFT Pharmaceuticals maintained a final dividend of 1.8 cents per share during the period, consistent with prior distributions. The most recent ex-dividend date was recorded as 18 June 2025, indicating the company has continued dividend payments to shareholders in subsequent years.
Outlook & Guidance
Management provided forward guidance indicating operating earnings for the year to 31 March 2020 are forecast to rise to between $9.0 million and $12.0 million. This guidance suggests potential earnings growth of between 50% and 100% compared to FY2019 EBIT, indicating management confidence in operational momentum heading into the new financial year.
What This Means
AFT Pharmaceuticals' FY2019 results indicate a company in transition, moving from loss-making to profitability. The modest revenue growth combined with significantly improved earnings suggests operational leverage and cost management may be taking effect. The company's governance rating of 77.24/100 reflects solid corporate standards. Investors should review the full financial statements and forward guidance in context of broader market conditions and competitive positioning within the healthcare sector.
---
This article was generated from structured NZX data by NZXplorer's automated reporting system. It is provided for informational purposes only and does not constitute financial advice. Data sourced from NZX company announcements and public filings. Always consult a licensed financial adviser before making investment decisions.